{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:40:07Z","timestamp":1785451207430,"version":"3.56.0"},"reference-count":40,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Severe nephrotic syndrome (NS) is associated with high risk of venous thromboembolic events (VTE), as well as presumably altered heparin pharmacokinetics and pharmacodynamics. Although prophylactic anticoagulation is recommended, the optimal dose is not established. The aim of the study was to test two co-primary hypotheses: of reduced enoxaparin effectiveness and of the need for dose-adjustment in NS. Forty two nephrotic patients with serum albumin \u22642.5 g\/dL were alternately assigned to a standard fixed-dose of enoxaparin (NS-FD: 40 mg\/day) or ideal body weight (IBW)-based adjusted-dose (NS-AD: 1 mg\/kg\/day). Twenty one matched non-proteinuric individuals (C-FD) also received fixed-dose. Co-primary outcomes were: the achievement of low- and high-VTE risk threshold of antifactor-Xa activity (anti-FXa) defined as 0.2 IU\/mL and 0.3 IU\/mL, respectively. Low-VTE-risk threshold was achieved less often in NS-FD than C-FD group (91 vs. 62%, p = 0.024), while the high-VTE-risk threshold more often in NS-AD than in NS-FD group (90 vs. 38%, p &lt; 0.001). Two VTE were observed in NS during 12 months of follow-up (incidence: 5.88%\/year). In both cases anti-FXa were 0.3 IU\/mL implying the use of anti-FXa &gt;0.3 IU\/mL as a target for dose-adjustment logistic regression models. We determined the optimal dose\/IBW cut-off value at 0.8 mg\/kg and further developed bivariate model (termed the DoAT model) including dose\/IBW and antithrombin activity that improved the diagnostic accuracy (AUC 0.85 \u00b1 0.06 vs. AUC 0.75 \u00b1 0.08). Enoxaparin efficacy is reduced in severe NS and the dose should be adjusted to ideal body weight to achieve target anti-FXa activity.<\/jats:p>","DOI":"10.3390\/jcm10235709","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T22:18:42Z","timestamp":1638829122000},"page":"5709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome\u2014A Single Center Prospective Study"],"prefix":"10.3390","volume":"10","author":[{"given":"Anna","family":"Matyjek","sequence":"first","affiliation":[{"name":"Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-9872","authenticated-orcid":false,"given":"Aleksandra","family":"Rymarz","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Nowicka","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Literacki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, Military Institute of Medicine, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Rozmyslowicz","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislaw","family":"Niemczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, 04-141 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"139","article-title":"Kidney disease: Improving global outcomes (KDIGO) glomerular diseases work group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Cattran","year":"2021","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome\u2014Associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ki.1985.149","article-title":"Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome","volume":"28","author":"Llach","year":"1985","journal-title":"Kidney Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kumar, S., Chapagain, A., Nitsch, D., and Yaqoob, M.M. (2012). Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: An observational study. BMC Nephrol., 13.","DOI":"10.1186\/1471-2369-13-107"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MAJ.0000000000000315","article-title":"Risk factors of pulmonary thrombosis\/embolism in nephrotic syndrome","volume":"348","author":"Yang","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fenton, A., Smith, S.W., and Hewins, P. (2018). Adult minimal-change disease: Observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0999-x"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","article-title":"A systematic review of prophylactic anticoagulation in nephrotic syndrome","volume":"5","author":"Lin","year":"2019","journal-title":"Kidney Int Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1440-1797.2002.00129.x","article-title":"Lack of efficacy of low molecular weight heparin in a boy with congenital nephrotic syndrome","volume":"7","author":"Girisch","year":"2002","journal-title":"Nephrology"},{"key":"ref_13","first-page":"190","article-title":"Above-standard proceeding in nephrotic syndrome\u2014Case report","volume":"40","author":"Matyjek","year":"2016","journal-title":"Pol. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.4081\/hr.2015.5844","article-title":"The anti-factor Xa range for low molecular weight heparin thromboprophylaxis","volume":"7","author":"Wei","year":"2015","journal-title":"Hematol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.soard.2015.08.505","article-title":"Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: Effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study","volume":"12","author":"Steib","year":"2016","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/PRS.0000000000003159","article-title":"Inadequate enoxaparin dosing predicts 90-day venous thromboembolism risk among plastic surgery inpatients: An examination of enoxaparin pharmacodynamics","volume":"139","author":"Pannucci","year":"2017","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MBC.0000000000000573","article-title":"The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: A retrospective study","volume":"28","author":"Boban","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.athoracsur.2018.02.085","article-title":"Enoxaparin 40 mg per day is inadequate for venous thromboembolism prophylaxis after thoracic surgical procedure","volume":"106","author":"Pannucci","year":"2018","journal-title":"Ann. Thorac. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.V78.9.2337.2337","article-title":"Identification of risk-factors for bleeding during treatment of acute venous thromboembolism with heparin or low-molecular-weight heparin","volume":"78","author":"Nieuwenhuis","year":"1991","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism","volume":"41","author":"Smythe","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1076-6332(97)80161-4","article-title":"Sampling variability of nonparametric estimates of the areas under receiver operating characteristic curves: An update","volume":"4","author":"Hanley","year":"1997","journal-title":"Acad. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000188703","article-title":"Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndrome","volume":"71","author":"Rossert","year":"1995","journal-title":"Nephron"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000188355","article-title":"Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin","volume":"69","author":"Rostoker","year":"1995","journal-title":"Nephron"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1046\/j.1365-2141.1999.01153.x","article-title":"Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery","volume":"104","author":"Bara","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5858\/2004-128-519-COPCPW","article-title":"Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study","volume":"128","author":"Desjardins","year":"2004","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","article-title":"Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment","volume":"105","author":"Sanderink","year":"2002","journal-title":"Thromb. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ki.2012.180","article-title":"The pathophysiology of edema formation in the nephrotic syndrome","volume":"82","author":"Siddall","year":"2012","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00467-007-0521-3","article-title":"Molecular mechanism of edema formation in nephrotic syndrome: Therapeutic implications","volume":"22","author":"Doucet","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(02)07920-5","article-title":"Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors","volume":"359","author":"Meijers","year":"2002","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/cc4952","article-title":"Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: A pilot study","volume":"10","author":"Rommers","year":"2006","journal-title":"Crit. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1440-1797.2010.01267.x","article-title":"Estimating the hydration status in nephrotic patients by leg electrical resistivity measuring method","volume":"15","author":"Jiang","year":"2010","journal-title":"Nephrology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3906\/sag-1312-132","article-title":"Bioimpedance for assessing volume status in children with nephrotic syndrome","volume":"45","author":"Mir","year":"2015","journal-title":"Turk. J. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.CCM.0000059725.60509.A0","article-title":"Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?","volume":"31","author":"Priglinger","year":"2003","journal-title":"Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2141.2001.02396.x","article-title":"Acquired antithrombin deficiency in sepsis","volume":"112","author":"White","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jcrc.2011.02.003","article-title":"Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients","volume":"26","author":"Vincent","year":"2011","journal-title":"J. Crit. Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200406000-00015","article-title":"Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment","volume":"26","author":"Hulot","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.thromres.2014.01.021","article-title":"Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: A systematic review and meta-analysis","volume":"133","author":"Ikesaka","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/TA.0000000000001142","article-title":"If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis","volume":"81","author":"Berndtson","year":"2016","journal-title":"J. Trauma Acute Care Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ndt\/gfw365","article-title":"Clinicopathologic correlations of renal pathology in adult population of Poland","volume":"32","author":"Bartczak","year":"2017","journal-title":"Nephrol. Dial. Transpl."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:40:18Z","timestamp":1760168418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/23\/5709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":40,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10235709"],"URL":"https:\/\/doi.org\/10.3390\/jcm10235709","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]}}}